-
Article
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
-
Article
Open AccessIbrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries. It has recently been shown that the homogeneity of the chromatin landscape between CLL cells contrasts with the important ...
-
Chapter
Laboratory Diagnosis of Chronic Lymphocytic Leukaemia
Chronic lymphocytic leukaemia (CLL) is one of the most common B-lymphoproliferative disorders (B-LPD) and is characterised by an expansion of monoclonal B-cells which are typically small lymphocytes with a nar...
-
Article
Open AccessAssessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now st...
-
Article
Open AccessGA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treat...
-
Chapter
Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
Waldenström macroglobulinaemia (WM) is a B-cell lymphoproliferative disorder characterised by IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic lymphoma (LPL). Historically LPL has be...
-
Article
Open AccessChemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Combination immunochemotherapy such as fludarabine, cyclophosphamide and rituximab is the standard first line therapy in fit patients, bu...
-
Article
Monoclonal B Cell Lymphocytosis—What Does It Really Mean?
Monoclonal B cell Lymphocytosis (MBL) or similar terms have been used for decades to describe the presence of light-chain restricted B lymphocytes with uncertain clinical significance, usually having a phenoty...
-
Article
Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?
Even though chronic lymphocytic leukemia (CLL) is the most prevalent leukemia of the Western world, the development of treatment approaches for CLL has lagged behind the development of approaches to various ot...
-
Article
Assessing minimal residual disease in chronic lymphocytic leukemia
New treatment approaches have substantially improved response rates in chronic lymphocytic leukemia. Accurate assessment of effective combination chemoimmunotherapy requires more sensitive measures of response...
-
Article
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism
Using FISH-based techniques, rearrangements of the immunoglobulin heavy-chain (IgH) locus at 14q32 have been found in the majority of cases of multiple myeloma (MM). Some of these IgH translocations are recurr...
